Tessa L. Holyoake

21 Shelley Road
Glasgow, SCT G120ZD, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications

Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy.

Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy.

Journal: Cancers
Published: June 30, 2022

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

Journal: Leukemia
Published: February 02, 2020

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia.

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia.

Journal: Cancer cell
Published: January 15, 2020

BRD4-mediated repression of p53 is a target for combination therapy in AML.

BRD4-mediated repression of p53 is a target for combination therapy in AML.

Journal: Nature communications
Published: October 18, 2019

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.

Journal: Leukemia
Published: August 08, 2019

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

Journal: Leukemia
Published: July 08, 2019

Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.

Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.

Journal: Leukemia
Published: March 21, 2018

Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells.

Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells.

Journal: Blood cells, molecules & diseases
Published: November 22, 2017

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.

Journal: Journal of the National Cancer Institute
Published: May 23, 2017

hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival.

hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival.

Journal: Blood
Published: May 12, 2017

A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients.

A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients.

Journal: Journal of hematology & oncology
Published: March 30, 2017

Validating a network hub in leukaemia stem cells.

Validating a network hub in leukaemia stem cells.

Journal: Oncoscience
Published: February 01, 2017
Showing 1-12 of 72

Last Updated: 09/26/2026